Todd K. Stevens1, Krishnan K. Palaniappan1,
Zachary M. Carrico1, Richard M. Ramirez1, Matthew B.
Francis1, David E. Wemmer1, Alexander Pines1
1Chemistry,
Molecular imaging aims to detect the presence and spatial distribution of
specific biomarkers in tissue. However, for many diseases the detection of
these biomarkers must be done at very low concentrations to maximize
diagnostic and prognostic value. Due to lack of sensitivity in conventional
MRI techniques, exogenous contrast agents (e.g. SPIO, PARACEST) are being
widely studied to lower concentration detection thresholds. Recently,
targeted hyperpolarized xenon-based biosensors that exploit the exchange of
solvated 129Xe between bulk solution (XeW) and cryptophane-A (CryA) molecular
cages (XeC) have demonstrated high sensitivity (1). To build upon this work,
a filamentous bacteriophage M13 was chosen as a scaffold upon which a large
number of CryA copies could be assembled. M13 bacteriophage are routinely employed
in phage display techniques used in panning for targeting moieties such as
single chain fragment antibodies (scFv) (2), and thus can be
straightforwardly targeted to biomarkers allowing for drastically increased
CryA payloads per bound target. The purpose
of this study was to investigate the feasibility of using an M13
bacteriophage modified with cryptophane-A molecular cages as a sensitive
xenon-based MR contrast agent and to determine the detection thresholds of
CryA-modified phage.